Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00085540
Other study ID # NCI-2012-02596
Secondary ID NABTC-0303U01CA0
Status Completed
Phase Phase 1/Phase 2
First received June 10, 2004
Last updated February 1, 2013
Start date January 2005

Study information

Verified date January 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I/II trial is studying the side effects and best dose of FR901228 and to see how well it works in treating patients with recurrent high-grade gliomas. FR901228 may stop the growth of tumor cells by blocking the enzymes necessary for their growth


Description:

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose (MTD) of FR901228 (depsipeptide) in patients with recurrent malignant gliomas who are taking enzyme-inducing antiepileptic drugs (EIAEDs). (Phase I) II. Determine the safety profile of this drug in these patients. (Phase I) III. Determine the pharmacokinetics and pharmacodynamics of this drug in these patients. (Phase I) IV. Determine the clinical efficacy of this drug, as measured by 6-month progression-free survival and objective tumor response, in these patients. (Phase II) V. Determine the safety profile of this drug when administered at the phase I MTD concurrently with or without EIAEDs in these patients. (Phase II)

OUTLINE: This is a multicenter, phase I, dose-escalation study followed by a phase II study. Patients are stratified according to study phase (I vs II), concurrent use of enzyme-inducing anti-epileptic drugs (EIAEDs) (yes vs no), histology (recurrent glioblastoma multiforme/gliosarcoma vs recurrent anaplastic glioma), pre-operative candidacy (yes vs no), and measurable/evaluable disease (yes vs no). Patients are assigned to 1 of 2 treatment groups (group A: no EIAEDs or group B: concurrent use of EIAEDs).

Phase I (group B only): Patients receive FR901228 (depsipeptide) IV over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of FR901228 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of up to 6 patients experience dose-limiting toxicity.

Phase II (groups A and B):

Group A (phase II): Patients receive FR901228 as in phase I at dose level 1. Group B (phase II): Patients receive FR901228 as in phase I at the MTD.


Other known NCT identifiers
  • NCT00103909

Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Phase I and phase II:

- Histologically confirmed recurrent intracranial malignant glioma, including any of the following:

- Glioblastoma multiforme

- Gliosarcoma

- Anaplastic astrocytoma

- Anaplastic oligodendroglioma

- Anaplastic mixed oligoastrocytoma

- Malignant astrocytoma not otherwise specified

- Unequivocal evidence of tumor progression by MRI or CT scan while on a steroid dosage that has been stable for at least 5 days

- Patients previously treated with interstitial brachytherapy or stereotactic radiosurgerymust have confirmation of true progressive disease (rather than radiation necrosis) by positron-emission tomography, thallium scan, magnetic resonance spectroscopy, or surgical documentation

- Must have failed prior radiotherapy that was completed at least 6 weeks ago

- No more than 2 prior therapies (initial treatment and treatment for 1 relapse)*

- Surgical resection for relapsed disease with no anticancer therapy for up to 12 weeks, followed by a second surgical resection, is considered treatment for 1 relapse

- Patients in group B must have been receiving enzyme-inducing antiepileptic drugs (EIAEDs) for at least the past 2 weeks

- Performance status - Karnofsky 60-100%

- More than 8 weeks

- WBC = 3,000/mm^3

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

- Hemoglobin = 10 g/dL (transfusions allowed)

- SGOT < 2 times upper limit of normal (ULN)

- Bilirubin < 2 times ULN

- Creatinine < 1.5 mg/dL

- No congestive heart failure (i.e., New York Heart Association class II-IV, ejection fraction < 40% by MUGA scan or < 50% by echocardiogram and/or MRI)

- No myocardial infarction within the past year

- No uncontrolled dysrhythmias

- No poorly controlled angina

- No significant left ventricular hypertrophy by EKG

- No cardiac ischemia (ST depression of 2 mm) by EKG

- No hypertrophic or restrictive cardiomyopathy from prior treatment or other causes

- No uncontrolled hypertension (i.e., blood pressure = 160/95 mm Hg)

- No cardiac arrhythmia requiring antiarrhythmic medication

- No known cardiac abnormalities (e.g., congenital long QT syndrome and QTc interval > 480 milliseconds)

- No history of sustained ventricular tachycardia, ventricular fibrillation, Torsade de Pointes, or cardiac arrest unless controlled with concurrent automatic implantable cardioverter defibrillator

- No known history of coronary artery disease (e.g., Canadian class II-IV angina)

- No other significant cardiac disease

- No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix

- No active infection

- No significant uncontrolled medical illness that would preclude study participation

- No disease that would obscure toxicity or dangerously alter drug metabolism

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception during and for at least 2 weeks after study participation

- Fertile male patients must continue barrier contraception for 3 months after study participation

- At least 1 week since prior interferon or thalidomide

- No concurrent prophylactic filgrastim (G-CSF)

- No concurrent anticancer immunotherapy

- At least 2 weeks since prior vincristine

- At least 6 weeks since prior nitrosoureas

- At least 3 weeks since prior procarbazine

- No prior FR901228 (depsipeptide)

- No other concurrent anticancer chemotherapy

- See Disease Characteristics

- At least 1 week since prior tamoxifen

- No concurrent anticancer hormonal therapy

- See Disease Characteristics

- No concurrent anticancer radiotherapy

- See Disease Characteristics

- Prior recent resection of recurrent or progressive tumor allowed if patient has recovered

- Recovered from all prior therapy

- At least 2 weeks since prior EIAEDs (patients in Group A only)

- At least 4 weeks since prior cytotoxic therapy

- At least 4 weeks since prior investigational agents

- At least 1 week since prior isotretinoin

- At least 1 week since other prior non-cytotoxic therapy (except radiosensitizers)

- No concurrent valproic acid

- No concurrent hydrochlorothiazide

- No concurrent medication that causes QTc prolongation

- No other concurrent anticancer therapy

- No other concurrent investigational drugs

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
romidepsin
Given IV

Locations

Country Name City State
United States North American Brain Tumor Consortium Watertown Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of depsipeptide determined by dose-limiting toxicities graded according to the NCI Common Toxicity Criteria (CTCAE Version 3.0) (Phase I) First 4 weeks of treatment Yes
Primary Progression-free survival (Phase II) At 6 months No
Secondary Response rate associated with depsipeptide therapy (Phase II) Up to No
See also
  Status Clinical Trial Phase
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00238303 - Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme Phase 2
Completed NCT02227901 - Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Completed NCT00049387 - Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma Phase 1
Completed NCT02015819 - Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Phase 1
Active, not recruiting NCT02179086 - Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Phase 2
Active, not recruiting NCT00823797 - Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma Phase 2
Completed NCT00045565 - Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT00045708 - A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas Phase 1/Phase 2
Completed NCT01977677 - Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma Phase 1/Phase 2
Completed NCT01648348 - Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00004262 - Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme Phase 1
Terminated NCT01575275 - Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme Phase 2
Terminated NCT01996527 - 3T MRI Biomarkers of Glioma Treatment Response Early Phase 1
Completed NCT01119599 - RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Phase 1
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Terminated NCT01103375 - Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma Phase 1
Completed NCT00459381 - Pazopanib in Treating Patients With Recurrent Glioblastoma Phase 2
Completed NCT00316849 - Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Phase 1
Terminated NCT00006773 - Bortezomib in Treating Patients With Recurrent Glioma Phase 1